Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 plus trastuzumab versus lapatinib plus capecitabine in trastuzumab-resistant HER2-positive advanced breast cancer
NL-OMON35443Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dactolisib, trastuzumab, lapatinib and capecitabine in breast cancer (3 arms), sponsored by Novartis. Primary endpoint: Incidence of dose-limiting toxicities. Planned start Jan 2012; status: withdrawn.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON35443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35443.